$1.64 Billion is the total value of Cormorant Asset Management, LP's 75 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 15.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TPTX | Buy | TURNING POINT THERAPEUTICS I | $133,155,000 | +4.8% | 3,541,367 | +13.4% | 8.10% | +11.0% |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $124,656,000 | +10.0% | 1,600,000 | +45.5% | 7.59% | +16.6% |
| SPY | New | SPDR S&P 500 ETF TRput | $118,708,000 | – | 400,000 | +100.0% | 7.23% | – |
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $71,692,000 | -4.6% | 2,976,000 | +0.3% | 4.36% | +1.1% |
| RETA | Buy | REATA PHARMACEUTICALS INCcl a | $65,819,000 | -13.5% | 819,769 | +1.7% | 4.01% | -8.3% |
| BBIO | Sell | BRIDGEBIO PHARMA INC | $56,199,000 | -25.1% | 2,617,566 | -5.9% | 3.42% | -20.6% |
| BHVN | Sell | BIOHAVEN PHARMACTL HLDG CO L | $53,460,000 | -21.2% | 1,281,400 | -17.3% | 3.25% | -16.5% |
| ASND | Buy | ASCENDIS PHARMA A Ssponsored adr | $45,107,000 | -2.1% | 468,300 | +17.1% | 2.75% | +3.8% |
| CRSP | Buy | CRISPR THERAPEUTICS AGnamen akt | $44,445,000 | +34.8% | 1,084,300 | +54.9% | 2.70% | +42.8% |
| MRTX | New | MIRATI THERAPEUTICS INCput | $42,851,000 | – | 550,000 | +100.0% | 2.61% | – |
| STOK | Sell | STOKE THERAPEUTICS INC | $38,433,000 | -29.5% | 1,788,394 | -4.3% | 2.34% | -25.3% |
| PRNB | Sell | PRINCIPIA BIOPHARMA INC | $37,895,000 | -16.2% | 1,341,896 | -1.5% | 2.31% | -11.1% |
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $36,221,000 | +9.7% | 493,000 | +40.9% | 2.20% | +16.3% |
| QURE | Buy | UNIQURE NV | $35,424,000 | -24.5% | 900,000 | +50.0% | 2.16% | -19.9% |
| ALLK | Sell | ALLAKOS INC | $34,920,000 | +24.0% | 444,100 | -31.7% | 2.13% | +31.4% |
| TCDA | Sell | TRICIDA INC | $33,429,000 | -28.1% | 1,082,880 | -8.1% | 2.04% | -23.8% |
| AXNX | Sell | AXONICS MODULATION TECH INC | $32,914,000 | -35.9% | 1,222,671 | -2.4% | 2.00% | -32.0% |
| XBI | Sell | SPDR SERIES TRUSTput | $30,500,000 | -61.4% | 400,000 | -55.6% | 1.86% | -59.0% |
| QTNT | Sell | QUOTIENT LTD | $28,298,000 | -20.4% | 3,642,000 | -4.2% | 1.72% | -15.6% |
| NXTC | Sell | NEXTCURE INC | $27,290,000 | +82.2% | 884,600 | -11.5% | 1.66% | +93.1% |
| DCPH | New | DECIPHERA PHARMACEUTICALS IN | $26,762,000 | – | 788,500 | +100.0% | 1.63% | – |
| BHVN | Buy | BIOHAVEN PHARMACTL HLDG CO Lcall | $25,032,000 | +3.9% | 600,000 | +9.1% | 1.52% | +10.2% |
| RCKT | Buy | ROCKET PHARMACEUTICALS INC | $24,742,000 | -20.5% | 2,123,760 | +2.4% | 1.51% | -15.7% |
| ASND | ASCENDIS PHARMA A Scall | $24,080,000 | -16.4% | 250,000 | 0.0% | 1.47% | -11.4% | |
| MYOK | Sell | MYOKARDIA INC | $23,102,000 | -7.9% | 443,000 | -11.4% | 1.41% | -2.4% |
| YMAB | Sell | Y-MABS THERAPEUTICS INC | $23,032,000 | +0.7% | 883,800 | -11.6% | 1.40% | +6.7% |
| GLPG | Sell | GALAPAGOS NVspon adr | $22,854,000 | +1.2% | 150,000 | -14.3% | 1.39% | +7.2% |
| ANAB | Sell | ANAPTYSBIO INC | $20,686,000 | -47.6% | 591,200 | -15.5% | 1.26% | -44.5% |
| AMRN | Buy | AMARIN CORP PLCspons adr new | $20,193,000 | +108.3% | 1,332,000 | +166.4% | 1.23% | +120.6% |
| EIDX | Sell | EIDOS THERAPEUTICS INC | $19,448,000 | +13.4% | 540,686 | -2.0% | 1.18% | +20.2% |
| KURA | Sell | KURA ONCOLOGY INC | $18,682,000 | -32.2% | 1,231,500 | -12.0% | 1.14% | -28.2% |
| AKRO | Sell | AKERO THERAPEUTICS INC | $16,849,000 | +14.6% | 740,621 | -3.5% | 1.03% | +21.4% |
| SRPT | Sell | SAREPTA THERAPEUTICS INC | $16,698,000 | -51.2% | 221,700 | -1.5% | 1.02% | -48.3% |
| TWST | Sell | TWIST BIOSCIENCE CORP | $16,409,000 | -19.9% | 687,149 | -2.7% | 1.00% | -15.1% |
| MRTX | MIRATI THERAPEUTICS INCcall | $15,582,000 | -24.4% | 200,000 | 0.0% | 0.95% | -19.8% | |
| ARGX | Sell | ARGENX SEsponsored adr | $14,599,000 | -31.3% | 128,110 | -14.6% | 0.89% | -27.1% |
| NKTR | Buy | NEKTAR THERAPEUTICS | $14,368,000 | +1.0% | 788,800 | +97.2% | 0.88% | +7.1% |
| STSA | New | SATSUMA PHARMACEUTICALS INC | $12,884,000 | – | 858,382 | +100.0% | 0.78% | – |
| SAGE | Sell | SAGE THERAPEUTICS INC | $12,444,000 | -32.0% | 88,700 | -11.3% | 0.76% | -28.0% |
| CCXI | Sell | CHEMOCENTRYX INC | $12,340,000 | -43.9% | 1,820,000 | -23.1% | 0.75% | -40.5% |
| HSACU | HEALTH SCIENCES ACQUISITN CORPunit 04/01/2024 | $11,588,000 | +1.2% | 1,080,000 | 0.0% | 0.70% | +7.1% | |
| XFOR | Sell | X4 PHARMACEUTICALS INC | $11,206,000 | -16.1% | 881,681 | -1.0% | 0.68% | -11.1% |
| INSP | Sell | INSPIRE MED SYS INC | $10,514,000 | -13.3% | 172,300 | -13.8% | 0.64% | -8.2% |
| GOSS | Sell | GOSSAMER BIO INC | $10,378,000 | -27.2% | 618,129 | -3.9% | 0.63% | -22.8% |
| EIGR | Sell | EIGER BIOPHARMACEUTICALS INC | $10,228,000 | -16.1% | 997,892 | -13.2% | 0.62% | -11.0% |
| ZLAB | Sell | ZAI LAB LTDadr | $8,966,000 | -14.3% | 277,161 | -7.6% | 0.55% | -9.2% |
| HARP | HARPOON THERAPEUTICS INC | $8,879,000 | +5.1% | 649,994 | 0.0% | 0.54% | +11.3% | |
| AVRO | Buy | AVROBIO INC | $8,024,000 | +79.4% | 568,294 | +106.7% | 0.49% | +89.9% |
| ORTX | Sell | ORCHARD THERAPEUTICS PLCads | $8,023,000 | -21.5% | 675,325 | -7.5% | 0.49% | -16.9% |
| ARNA | Sell | ARENA PHARMACEUTICALS INC | $7,886,000 | -32.7% | 172,300 | -13.8% | 0.48% | -28.8% |
| CNST | Sell | CONSTELLATION PHARMACEUTICAL I | $7,838,000 | -49.8% | 1,213,274 | -4.6% | 0.48% | -46.8% |
| RARX | Sell | RA PHARMACEUTICALS INC | $6,991,000 | -33.6% | 295,600 | -15.5% | 0.43% | -29.6% |
| AUTL | Sell | AUTOLUS THERAPEUTICS PLCspon ads | $5,961,000 | -47.1% | 479,988 | -31.4% | 0.36% | -43.9% |
| GNFT | Sell | GENFIT S Aads | $5,223,000 | -17.3% | 300,000 | -6.2% | 0.32% | -12.4% |
| BCEL | Sell | ATRECA INC | $4,971,000 | -40.7% | 406,142 | -8.7% | 0.30% | -37.1% |
| NERV | MINERVA NEUROSCIENCES INC | $4,711,000 | +37.7% | 607,903 | 0.0% | 0.29% | +45.7% | |
| FIXX | Sell | HOMOLOGY MEDICINES INC | $4,436,000 | -24.4% | 245,100 | -18.3% | 0.27% | -19.9% |
| ATRA | Sell | ATARA BIOTHERAPEUTICS INC | $4,236,000 | -47.3% | 300,000 | -25.0% | 0.26% | -44.2% |
| DTIL | PRECISION BIOSCIENCES INC | $3,922,000 | -36.7% | 467,518 | 0.0% | 0.24% | -32.9% | |
| RUBY | Sell | RUBIUS THERAPEUTICS INC | $3,860,000 | -59.1% | 491,700 | -18.0% | 0.24% | -56.6% |
| NBIX | Sell | NEUROCRINE BIOSCIENCES INC | $3,541,000 | -16.1% | 39,300 | -21.4% | 0.22% | -11.1% |
| PHAS | Sell | PHASEBIO PHARMACEUTICALS INC | $3,405,000 | -71.4% | 816,448 | -9.9% | 0.21% | -69.7% |
| KZR | Sell | KEZAR LIFE SCIENCES INC | $3,043,000 | -59.2% | 927,869 | -4.2% | 0.18% | -56.9% |
| IGMS | New | IGM BIOSCIENCES INC | $2,776,000 | – | 156,400 | +100.0% | 0.17% | – |
| ITRM | ITERUM THERAPEUTICS PLC | $2,339,000 | -14.2% | 396,385 | 0.0% | 0.14% | -9.6% | |
| ADVM | New | ADVERUM BIOTECHNOLOGIES INCcall | $1,635,000 | – | 300,000 | +100.0% | 0.10% | – |
| BOLD | Sell | AUDENTES THERAPEUTICS INC | $1,405,000 | -50.5% | 50,000 | -33.3% | 0.09% | -47.2% |
| SRRK | Sell | SCHOLAR ROCK HLDG CORP | $1,065,000 | -55.2% | 118,950 | -20.7% | 0.06% | -52.6% |
| GTHX | New | G1 THERAPEUTICS INC | $1,025,000 | – | 1,000 | +100.0% | 0.06% | – |
| XLRN | Sell | ACCELERON PHARMA INC | $988,000 | -39.9% | 25,000 | -37.5% | 0.06% | -36.2% |
| IFRX | Sell | INFLARX NV | $741,000 | -84.4% | 300,000 | -80.0% | 0.04% | -83.5% |
| ABEO | Sell | ABEONA THERAPEUTICS INC | $452,000 | -73.0% | 200,000 | -42.9% | 0.03% | -70.8% |
| ACRS | ACLARIS THERAPEUTICS INC | $270,000 | -50.7% | 250,000 | 0.0% | 0.02% | -48.4% | |
| OTLKW | OUTLOOK THERAPEUTICS INC*w exp 02/18/202 | $50,000 | +8.7% | 416,666 | 0.0% | 0.00% | 0.0% | |
| OTLK | Buy | OUTLOOK THERAPEUTICS INC | $23,000 | -28.1% | 15,753 | +0.0% | 0.00% | -50.0% |
| CLRBW | Exit | CELLECTAR BIOSCIENCES INC*w exp 08/20/201 | $0 | – | -52,999 | -100.0% | 0.00% | – |
| QURE | Exit | UNIQURE NVcall | $0 | – | -100,000 | -100.0% | -0.45% | – |
| VRTX | Exit | VERTEX PHARMACEUTICALS INC | $0 | – | -85,000 | -100.0% | -0.90% | – |
| ARRY | Exit | ARRAY BIOPHARMA INC | $0 | – | -450,000 | -100.0% | -1.20% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
| SC 13G/A | 2024-03-18 |
| 4 | 2024-03-11 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.